Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . RemeGen 荣昌 生物 RemeGen Co. , Ltd. * 榮昌 生物 製藥 ( 煙台 ) 股份有限公司 ( A joint stock company incorporated in the People's Republic of China with limited liability ) ( Stock Code : 9995 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2026 The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended June 30 , 2026 , together with the comparative figures for the corresponding period in 2025 . BUSINESS HIGHLIGHTS During the Reporting Period , we have made significant progress in advancing commercialization , product pipeline as well as business operations : COMMERCIALIZATION The Group recorded revenue from product sales , research and development and license services of approximately RMB5,850.2 million for the six months ended June 30 , 2026 , representing an increase of 435.74 % from RMB1,092.0 million in the corresponding period of last year , mainly attributable to robust sales growth of telitacicept ( RC18 , brand name : ** ® ) , a commercial - stage product of the Company for the treatment of autoimmune diseases , and disitamab vedotin ( RC48 , brand name : ® ) , a commercial - stage product of the Company for the treatment of tumors . The Company entered into an exclusive license agreement with AbbVie Inc. ( " Abbvie " ) for RC148 , pursuant to which AbbVie will obtain exclusive rights to develop , manufacture and commercialize RC148 outside of Greater China , resulting in a significant increase in technology license revenue .